Modality
siRNA
MOA
WEE1i
Target
TNFα
Pathway
NF-κB
Ovarian Ca
Development Pipeline
Preclinical
~Oct 2021
→ ~Jan 2023
Phase 1
Apr 2023
→ Mar 2027
Phase 1Current
NCT06555260
1,752 pts·Ovarian Ca
2023-04→2027-03·Not yet recruiting
1,752 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-03-1411mo awayInterim· Ovarian Ca
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P1
Not yet…
Catalysts
Interim
2027-03-14 · 11mo away
Ovarian Ca
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06555260 | Phase 1 | Ovarian Ca | Not yet recr... | 1752 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| 369-4107 | Hansoh Pharma | Phase 2 | TNFα | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 |